Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NIFK pseudogene 6 (NIFKP6) is classified as a pseudogene in the human genome[3][5]. It is related by sequence to the protein-coding gene NIFK (nucleolar protein interacting with the FHA domain of MKI67), which encodes a protein known to interact with the Ki-67 antigen involved in cell cycle regulation[2][7]. Unlike its protein-coding counterpart, NIFKP6 does not encode a functional protein. Pseudogenes such as NIFKP6 are generally considered genomic DNA segments that share high sequence similarity with functional genes but contain mutations or defects that preclude their translation into a functional product[5]. Some pseudogenes have been found to exert biological effects through regulatory RNA mechanisms, but there is currently no published evidence indicating any functional, regulatory, or pathogenic role for NIFKP6 specifically[3][5]. It is not considered a therapeutic target, receptor, enzyme, or biomarker, and it has no known disease associations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NIFK pseudogene 6 (NIFKP6).